In contrast, IL-6 antibodies failed in phase II clinical trials for IBD due to non-tolerable side effects (17, 18), including intestinal perforations which were also observed for anti-IL-6R therapy for rheumatoid arthritis (19). Here, IL6R is linked to rheumatoid arthritis.